NIH T32 Research Fellow
Massachusetts General Hospital, Harvard Medical School, United States
Riddha Das specializes in nanomaterials, biomedical engineering, and immunology, focusing on developing cancer vaccines and therapeutics. During PhD, she worked on surface engineering of nanoparticles for targeted therapy and imaging. During postdoctoral research, Riddha developed novel drug delivery systems, engineered dendritic cell-based adoptive cell therapy, and novel mRNAs to generate anti-tumor immunities through unique pathways, resulting in over 25 publications and two patents.
Disclosure information not submitted.
Hybrid LNP prime dendritic cells for nucleotide delivery
Tuesday, July 15, 2025
11:05 AM – 11:16 AM EDT